Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
Summary
All studies
Mortality
ICU
Hospitalization
Serious outcomes
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Nitazoxanide  COVID-19 treatment studies for Nitazoxanide  C19 studies: Nitazoxanide  Nitazoxanide   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Metformin
Bamlanivimab Molnupiravir
Bromhexine Nigella Sativa
Budesonide Nitazoxanide
Casirivimab/i.. Povidone-Iod..
Colchicine Probiotics
Conv. Plasma Proxalutamide
Curcumin Quercetin
Favipiravir Remdesivir
Fluvoxamine Sotrovimab
Hydroxychloro.. Vitamin A
Iota-carragee.. Vitamin C
Ivermectin Vitamin D
Melatonin Zinc

Other Adoption
Outcomes in COVID-19 nitazoxanide studies
00.250.50.7511.251.51.752+All studies55%61,464Improvement, Studies, PatientsRelative Risk, 95% CIMortality60%3923ICU admission-404%1392Hospitalization71%41,315Viral clearance60%4583RCTs25%4857Peer-reviewed73%41,049Early49%51,414Late67%150Nitazoxanide for COVID-19c19nitazoxanide.com Oct 20, 2021Favors nitazoxanideFavors control
00.250.50.7511.251.51.752+Rocco (RCT)-404%5.04 [0.24-104]ICU2/1940/198Improvement, RR [CI]TreatmentControlCadegiani88%0.12 [0.01-2.52]death0/3572/137Elalfy87%0.13 [0.06-0.27]viral+7/6244/51CT​1Silva (SB RCT)26%0.74 [0.38-1.41]viral+23 (n)13 (n)Rossignol (DB RCT)-206%3.06 [0.13-74.6]death1/1840/195Tau​2 = 1.35; I​2 = 77.4%Early treatment49%0.51 [0.13-1.95]10/82046/59449% improvementBlum (DB RCT)67%0.33 [0.07-1.50]death2/256/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment67%0.33 [0.07-1.50]2/256/2567% improvementAll studies55%0.45 [0.15-1.35]12/84552/61955% improvement6 nitazoxanide COVID-19 studiesc19nitazoxanide.com Oct 20, 20211 CT: study uses combined treatmentTau​2 = 1.03; I​2 = 71.7%; Z = 1.42Effect extraction pre-specifiedFavors nitazoxanideFavors control 00.250.50.7511.251.51.752+Cadegiani88%0.12 [0.01-2.52]0/3572/137Improvement, RR [CI]TreatmentControlRossignol (DB RCT)-206%3.06 [0.13-74.6]1/1840/195Tau​2 = 2.67; I​2 = 51.4%Early treatment41%0.59 [0.02-13.8]1/5412/33241% improvementBlum (DB RCT)67%0.33 [0.07-1.50]2/256/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment67%0.33 [0.07-1.50]2/256/2567% improvementAll studies60%0.40 [0.10-1.58]3/5668/35760% improvement3 nitazoxanide COVID-19 mortality resultsc19nitazoxanide.com Oct 20, 2021Tau​2 = 0.17; I​2 = 9.3%; Z = 1.31Favors nitazoxanideFavors control 00.250.50.7511.251.51.752+Rocco (RCT)-404%5.04 [0.24-104]2/1940/198Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment-404%5.04 [0.24-104]2/1940/198-404% improvementAll studies-404%5.04 [0.24-104]2/1940/198-404% improvement1 nitazoxanide COVID-19 ICU resultc19nitazoxanide.com Oct 20, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.05Favors nitazoxanideFavors control 00.250.50.7511.251.51.752+Rocco (RCT)-2%1.02 [0.30-3.47]hosp.5/1945/198Improvement, RR [CI]TreatmentControlCadegiani99%0.01 [0.00-0.17]hosp.0/35727/137Rossignol (DB RCT)79%0.21 [0.02-1.80]hosp.1/1845/195Tau​2 = 3.68; I​2 = 78.4%Early treatment83%0.17 [0.01-2.00]6/73537/53083% improvementBlum (DB RCT)56%0.44 [0.22-0.89]hosp. time25 (n)25 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment56%0.44 [0.22-0.89]0/250/2556% improvementAll studies71%0.29 [0.08-1.06]6/76037/55571% improvement4 nitazoxanide COVID-19 hospitalization resultsc19nitazoxanide.com Oct 20, 2021Tau​2 = 1.06; I​2 = 67.6%; Z = 1.88Favors nitazoxanideFavors control 00.250.50.7511.251.51.752+Rocco (RCT)-404%5.04 [0.24-104]ICU2/1940/198Improvement, RR [CI]TreatmentControlCadegiani88%0.12 [0.01-2.52]death0/3572/137Rossignol (DB RCT)-206%3.06 [0.13-74.6]death1/1840/195Tau​2 = 1.71; I​2 = 40.9%Early treatment-21%1.21 [0.12-12.3]3/7352/530-21% improvementBlum (DB RCT)67%0.33 [0.07-1.50]death2/256/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment67%0.33 [0.07-1.50]2/256/2567% improvementAll studies31%0.69 [0.15-3.29]5/7608/55531% improvement4 nitazoxanide COVID-19 serious outcomesc19nitazoxanide.com Oct 20, 2021Tau​2 = 0.88; I​2 = 33.9%; Z = 0.46Effect extraction pre-specifiedFavors nitazoxanideFavors control 00.250.50.7511.251.51.752+Rocco (RCT)12%0.88 [0.80-0.96]viral+194 (n)198 (n)Improvement, RR [CI]TreatmentControlElalfy87%0.13 [0.06-0.27]viral+7/6244/51CT​1Silva (SB RCT)26%0.74 [0.38-1.41]viral+23 (n)13 (n)Tau​2 = 0.78; I​2 = 92.8%Early treatment54%0.46 [0.16-1.30]7/27944/26254% improvementBlum (DB RCT)90%0.10 [0.01-1.78]viral+0/234/19Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment90%0.10 [0.01-1.78]0/234/1990% improvementAll studies60%0.40 [0.15-1.09]7/30248/28160% improvement4 nitazoxanide COVID-19 viral clearance resultsc19nitazoxanide.com Oct 20, 20211 CT: study uses combined treatmentTau​2 = 0.79; I​2 = 89.9%; Z = 1.79Favors nitazoxanideFavors control 00.250.50.7511.251.51.752+Rocco (RCT)-404%5.04 [0.24-104]ICU2/1940/198Improvement, RR [CI]TreatmentControlSilva (SB RCT)26%0.74 [0.38-1.41]viral+23 (n)13 (n)Rossignol (DB RCT)-206%3.06 [0.13-74.6]death1/1840/195Tau​2 = 0.09; I​2 = 6.3%Early treatment8%0.92 [0.41-2.08]3/4010/4068% improvementBlum (DB RCT)67%0.33 [0.07-1.50]death2/256/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment67%0.33 [0.07-1.50]2/256/2567% improvementAll studies25%0.75 [0.36-1.55]5/4266/43125% improvement4 nitazoxanide COVID-19 Randomized Controlled Trialsc19nitazoxanide.com Oct 20, 2021Tau​2 = 0.09; I​2 = 11.3%; Z = 0.78Effect extraction pre-specifiedFavors nitazoxanideFavors control 00.250.50.7511.251.51.752+Rossignol (DB RCT)-206%3.06 [0.13-74.6]1/1840/195Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment-206%3.06 [0.13-74.6]1/1840/195-206% improvementBlum (DB RCT)67%0.33 [0.07-1.50]2/256/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment67%0.33 [0.07-1.50]2/256/2567% improvementAll studies37%0.63 [0.09-4.54]3/2096/22037% improvement2 nitazoxanide COVID-19 RCT mortality resultsc19nitazoxanide.com Oct 20, 2021Tau​2 = 0.84; I​2 = 34.0%; Z = 0.45Favors nitazoxanideFavors control 00.250.50.7511.251.51.752+Rocco (RCT)-404%5.04 [0.24-104]ICU2/1940/198Improvement, RR [CI]TreatmentControlCadegiani88%0.12 [0.01-2.52]death0/3572/137Elalfy87%0.13 [0.06-0.27]viral+7/6244/51CT​1Tau​2 = 2.14; I​2 = 62.4%Early treatment68%0.32 [0.04-2.58]9/61346/38668% improvementBlum (DB RCT)67%0.33 [0.07-1.50]death2/256/25Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment67%0.33 [0.07-1.50]2/256/2567% improvementAll studies73%0.27 [0.08-0.94]11/63852/41173% improvement4 nitazoxanide COVID-19 peer reviewed trialsc19nitazoxanide.com Oct 20, 20211 CT: study uses combined treatmentTau​2 = 0.76; I​2 = 51.1%; Z = 2.06Effect extraction pre-specifiedFavors nitazoxanideFavors control 00.250.50.7511.251.51.752+Rocco (RCT)-404%5.04 [0.24-104]ICU2/1940/198Improvement, RR [CI]TreatmentControlRocco (RCT)-2%1.02 [0.30-3.47]hosp.5/1945/198Rocco (RCT)-16%1.16 [0.84-1.59]no recov.59/19452/198Rocco (RCT)12%0.88 [0.80-0.96]viral+194 (n)198 (n)Rocco (RCT)14%0.86 [0.77-0.96]viral+136/194162/198Cadegiani88%0.12 [0.01-2.52]death0/3572/137Cadegiani97%0.03 [0.00-0.51]ventilation0/3579/137Cadegiani99%0.01 [0.00-0.17]hosp.0/35727/137Elalfy87%0.13 [0.06-0.27]viral+7/6244/51CT​1Elalfy58%0.42 [0.31-0.56]viral+26/6251/51CT​1Silva (SB RCT)26%0.74 [0.38-1.41]viral+23 (n)13 (n)Silva (SB RCT)38%0.62 [0.39-0.97]viral+12/2311/13Rossignol (DB RCT)-206%3.06 [0.13-74.6]death1/1840/195Rossignol (DB RCT)79%0.21 [0.02-1.80]hosp.1/1845/195Rossignol (DB RCT)85%0.15 [0.02-1.22]severe case1/1847/195Rossignol (DB RCT)84%0.16 [0.02-1.29]severe case1/1127/126Blum (DB RCT)67%0.33 [0.07-1.50]death2/256/25Blum (DB RCT)62%0.38 [0.11-1.25]ventilation3/258/25Blum (DB RCT)56%0.44 [0.22-0.89]hosp. time25 (n)25 (n)Blum (DB RCT)90%0.10 [0.01-1.78]viral+0/234/19nitazoxanide COVID-19 outcomesc19nitazoxanide.com Oct 20, 2021Favors nitazoxanideFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit